INS and type 2 diabetes mellitus: In the matched type 2 diabetes cohort, people with (without) GI used insulin therapy with or without additional oral antidiabetics/GLP-1 agonists in 46.2% (41.4%); 23.1% (24.0%) had lifestyle interventions only; 31.8% (34.6%) were treated with oral antidiabetic agents and/or GLP1-agonists only (all p>0.05).